Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global <scp>DISCOVER</scp> study-Reference-Cited by-同舟云学术

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study

Published:2022-09-16 Issue:1 Volume:25 Page:46-55
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Charbonnel Bernard H.¹^ORCID,Chen Hungta²,Cid‐Ruzafa Javier³,Cooper Andrew⁴,Fenici Peter⁵,Gomes Marilia B.⁶^ORCID,Saraiva Gabriela L.²,Medina Jesús⁷,Nicolucci Antonio⁸^ORCID,Shestakova Marina V.⁹,Shimomura Iichiro¹⁰,Surmont Filip¹¹,Tang Fengming¹²,Vora Jiten¹³,Watada Hirotaka¹⁴^ORCID,Khunti Kamlesh¹⁵^ORCID,

Affiliation:

1. Department of Endocrinology and Diabetes University of Nantes Nantes France

2. BioPharmaceuticals Medical AstraZeneca Gaithersburg Maryland USA

3. Evidera Barcelona Spain

4. BioPharmaceuticals Medical AstraZeneca Cambridge UK

5. BioPharmaceuticals Medical AstraZeneca Milan Italy

6. Department of Internal Medicine Rio de Janeiro State University Rio de Janeiro Brazil

7. BioPharmaceuticals Medical AstraZeneca Madrid Spain

8. Center for Outcomes Research and Clinical Epidemiology Pescara Italy

9. Endocrinology Research Centre, Diabetes Institute Moscow Russian Federation

10. Graduate School of Medicine Osaka University Osaka Japan

11. BioPharmaceuticals Medical AstraZeneca Luton UK